Table 1.
Participant characteristics stratified by HIV status
| Variables | HIV+ individuals (n = 2887) | HIV− individuals (n = 761) | Effect size (95% CI) | p value |
|---|---|---|---|---|
| Demographics | ||||
| Age (years), mean (SD) | 45.6 (11) | 44.9 (14) | 0.05 [− 0.02; 0.13]a | 0.9 |
| Education, mean (SD) | 12.9 (3) | 13.6 (4) | − 0.19 [− 0.27; − 0.11]a | < .0001 |
| Male, n (%) | 2333 (80.8%) | 501 (65.8%) | 2.18 [1.83; 2.61]b | < .0001 |
| Ethnicity, n (%) | ||||
| Hispanic | 503 (17.4) | 147 (19.3%) | < .0001 | |
| Non-Hispanic white | 1328 (46) | 430 (56.5%) | ||
| African American | 958 (33.2) | 136 (17.9%) | ||
| Asian | 25 (0.9) | 14 (1.9) | ||
| Other | 73 (2.5) | 34 (4.5) | ||
| BMI (kg/m2), mean (SD) | 26.6 (10) | 28.3 (6) | − 0.17 [− 0.29; − 0.09]a | < .0001 |
| Cannabis use, n (%) | ||||
| Cannabis ever used, n (%) | 1821 (74.9) | 408 (72.6) | 0.88 [0.72; 1.09]b | 0.2 |
| Lifetime years cannabis use, mean (SD) | 6.9 (8.4) | 7.2 (9.5) | − 0.03 [− 0.14; 0.07]a | 0.5 |
| Lifetime quantity cannabis (grams), mean (SD) | 4724 (12775) | 4515 (11627) | 0.01 [− 0.09; 0.12]a | 0.6 |
| Medication currently used, n (%) | ||||
| Opioids, n (%) | 480 (16.6) | 53 (6.9) | 2.66 [1.98; 3.58]b | <.0001 |
| Sedatives, n (%) | 365 (12.6) | 39 (5.1) | 2.75 [1.95; 3.87]b | <.0001 |
| Antihypertensives, n (%) | 223 (7.7) | 65 (8.5) | 0.9 [0.67; 1.21]b | 0.5 |
| Neurological disease, n (%) | ||||
| cDSPN signs, n (%) | 1574 (54.5) | 190 (24.9) | 3.60 [3.00; 4.31]b | <.0001 |
| Gait ataxia, n (%) | 130 (4.5) | 20 (2.6) | 1.74 [1.08; 2.81]b | 0.02 |
Effect size presented as aCohen’s d or bodds ratios
CI confidence interval, BMI body mass index, cDSPN chronic distal sensory polyneuropathy